[1]Alarcón G S, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: profile[J]. Lupus, 2002, 11(2): 95-101.
[2]Feldman C H, Hiraki L T, Liu Jun, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage[J]. Arthritis Rheum, 2013, 65(3): 753-763.
[3]Kronbichler A, Brezina B, Gauckler P, et al. Refractory lupus nephritis: when, why and how to treat[J]. Autoimmun Rev, 2019, 18(5): 510-518.
[4]张辉, 杨念生, 鲁静, 等. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-790.
[5]Liu Z H, Zhang H T, Liu Z S, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial[J]. Ann Intern Med, 2015, 162(1): 18-26.
[6]Struemper H, Kurtinecz M, Edwards L, et al. Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE[J]. Lupus Sci Med, 2022, 9(1): e000499.
[7]Stohl W, Hiepe F, Latinis K M, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(7): 2328-2337.
[8]Furie R, Rovin B H, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128.
[9]Rovin B H, Adler S G, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4): 753-779.
[10]Brad H R, Isabelle M A,TM Chan,et al.KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS[J].Kidney Int,2024,105(1S):S1-S69.
[11]Mejia-Vilet J M, Malvar A, Arazi A, et al. The lupus nephritis management Renaissance[J]. Kidney Int, 2022, 101(2): 242-255.
[12]Zhang J, Roschke V, Baker K P, et al. Cutting edge: a role for b lymphocyte stimulator in systemic lupus erythematosus[J]. J Immunol, 2001, 166(1): 6-10.
[13]Yu X Q, Chen N, Xue J, et al. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east Asian population[J]. Am J Kidney Dis, 2023, 81(3): 294-306.e1.
[14]赵院霞, 高冠民, 王松, 等. 贝利尤单抗治疗狼疮肾炎的临床疗效与安全性研究[J]. 中国医院药学杂志, 2022, 42(3): 288-292.
[15]Rovin B H, Furie R, Teng Y K O, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J]. Kidney Int, 2022, 101(2): 403-413.
[16]Ladouceur A, Tessier-Cloutier B, Clarke A E, et al. Cancer and systemic lupus erythematosus[J]. Rheum Dis Clin North Am, 2020, 46(3): 533-550.
[17]Hsu C Y, Lin M S, Su Y J, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study[J]. Rheumatology, 2017, 56(4): 620-628.
[18]DCruz D, Eriksson G, Green Y, et al. Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data[J]. Lupus Sci Med, 2023, 10(1): e000830.
[19]Doria A, Bass D, Schwarting A, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus[J]. Lupus, 2018, 27(9): 1489-1498.
[20]Ginzler E M, Wallace D J, Merrill J T, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus[J]. J Rheumatol, 2014, 41(2): 300-309.
[21]Doria A, Stohl W, Schwarting A, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2018, 70(8): 1256-1264.
|